Enhancer ID: | E_02_0270 |
Species: | human |
Position : | chr7:22723017-22725017 |
Biosample name: | |
Experiment class : | High+Lowthroughput |
Enhancer type: | Enhancer |
Disease: | Inflammatory |
Pubmed ID: | 30947238 |
Enhancer experiment: | Western blot? |
Enhancer experiment description: | The ?7 nAChR partial agonist GTS-21 reduces secretion of pro-inflammatory cytokines including interleukin-6 (IL6) and tumor-necrosis factor (TNF) in models of endotoxemia and sepsis, and its anti-inflammatory effects are widely ascribed to ?7 nAChR activation. |
Target gene : | IL6 |
Strong evidence: | qRT-PCR,qPCR,ChIP,3C |
Less strong evidence: | RNA-Seq |
Target gene experiment description: | The ?7 nAChR partial agonist GTS-21 reduces secretion of pro-inflammatory cytokines including interleukin-6 (IL6) and tumor-necrosis factor (TNF) in models of endotoxemia and sepsis, and its anti-inflammatory effects are widely ascribed to ?7 nAChR activation. |
TF name : | -- |
TF experiment: | Western blot? |
TF experiment description: | The ?7 nAChR partial agonist GTS-21 reduces secretion of pro-inflammatory cytokines including interleukin-6 (IL6) and tumor-necrosis factor (TNF) in models of endotoxemia and sepsis, and its anti-inflammatory effects are widely ascribed to ?7 nAChR activation. |
Enhancer function : | The ?7 nAChR partial agonist GTS-21 reduces secretion of pro-inflammatory cytokines including interleukin-6 (IL6) and tumor-necrosis factor (TNF) in models of endotoxemia and sepsis, and its anti-inflammatory effects are widely ascribed to ?7 nAChR activation. |
Enhancer function experiment: | Immunohistochemical staining |
Enhancer function experiment description: |
The ?7 nAChR partial agonist GTS-21 reduces secretion of pro-inflammatory cytokines including interleukin-6 (IL6) and tumor-necrosis factor (TNF) in models of endotoxemia and sepsis, and its anti-inflammatory effects are widely ascribed to ?7 nAChR activation. |
SNP ID: | -- |
GeneName | Pathway Name | Source | Gene Number |
---|